Zoryl 2 Tablet contains Glimepiride 2mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. Glimepiride acts by stimulating insulin secretion from pancreatic beta cells, thereby improving glycemic control in patients with inadequate response to diet and exercise alone. It is particularly useful in patients with preserved pancreatic function and can be used as monotherapy or in combination with other antidiabetic agents such as metformin or insulin. The onset of action typically occurs within 1 to 2 hours, with a duration of effect lasting up to 24 hours, allowing once-daily dosing. Zoryl 2 Tablet should be administered with breakfast or the first main meal to reduce the risk of hypoglycemia. Common adverse effects include hypoglycemia, weight gain, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and close monitoring of blood glucose levels is recommended during therapy initiation and dose adjustments. Zoryl 2 Tablet is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Regular monitoring of glycemic parameters and adherence to lifestyle modifications are essential to optimize therapeutic outcomes.